Malatesta M
Int J Mol Sci. 2024; 25(15).
PMID: 39125610
PMC: 11311594.
DOI: 10.3390/ijms25158041.
Joseph J, Gigliobianco M, Mahdavi Firouzabadi B, Censi R, Di Martino P
Pharmaceutics. 2022; 14(2).
PMID: 35214114
PMC: 8874484.
DOI: 10.3390/pharmaceutics14020382.
MacRitchie N, Di Francesco V, Ferreira M, Guzik T, Decuzzi P, Maffia P
Semin Immunol. 2021; 56:101536.
PMID: 34862118
PMC: 8811479.
DOI: 10.1016/j.smim.2021.101536.
Koshkina O, White P, Staal A, Schweins R, Swider E, Tirotta I
J Colloid Interface Sci. 2020; 565:278-287.
PMID: 31978790
PMC: 7058420.
DOI: 10.1016/j.jcis.2019.12.083.
Liu C, Zhou J, Cheng X, Xia L, Zhou J, Xu S
Contrast Media Mol Imaging. 2019; 2019:2783519.
PMID: 30804723
PMC: 6360587.
DOI: 10.1155/2019/2783519.
Vascular targeting of nanoparticles for molecular imaging of diseased endothelium.
Atukorale P, Covarrubias G, Bauer L, Karathanasis E
Adv Drug Deliv Rev. 2016; 113:141-156.
PMID: 27639317
PMC: 5352558.
DOI: 10.1016/j.addr.2016.09.006.
Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis.
Allen S, Liu Y, Scott E
Regen Eng Transl Med. 2016; 2(1):37-50.
PMID: 27135051
PMC: 4849406.
DOI: 10.1007/s40883-016-0012-9.
Recent Advances in Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions.
Schmieder A, Caruthers S, Keupp J, Wickline S, Lanza G
Engineering (Beijing). 2016; 1(4):475-489.
PMID: 27110430
PMC: 4841681.
DOI: 10.15302/J-ENG-2015103.
A bisphosphonate for F-magnetic resonance imaging.
Kenny G, Shaw K, Sivachelvam S, White A, Botnar R, T M de Rosales R
J Fluor Chem. 2016; 184:58-64.
PMID: 27110036
PMC: 4834630.
DOI: 10.1016/j.jfluchem.2016.02.008.
Targeting and therapeutic peptides in nanomedicine for atherosclerosis.
Chung E
Exp Biol Med (Maywood). 2016; 241(9):891-8.
PMID: 27022138
PMC: 4871742.
DOI: 10.1177/1535370216640940.
Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents.
Palekar R, Jallouk A, Lanza G, Pan H, Wickline S
Nanomedicine (Lond). 2015; 10(11):1817-32.
PMID: 26080701
PMC: 4483172.
DOI: 10.2217/nnm.15.26.
Inflammatory Stress Exacerbated Mesangial Foam Cell Formation and Renal Injury via Disrupting Cellular Cholesterol Homeostasis.
Zhong S, Zhao L, Li Q, Yang P, Varghese Z, Moorhead J
Inflammation. 2014; 38(3):959-71.
PMID: 25387652
DOI: 10.1007/s10753-014-0058-0.
Targeted nanotechnology for cancer imaging.
Toy R, Bauer L, Hoimes C, Ghaghada K, Karathanasis E
Adv Drug Deliv Rev. 2014; 76:79-97.
PMID: 25116445
PMC: 4169743.
DOI: 10.1016/j.addr.2014.08.002.
Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent.
Winter P
Scientifica (Cairo). 2014; 2014:746574.
PMID: 25024867
PMC: 4082945.
DOI: 10.1155/2014/746574.
Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus.
Bruckman M, Jiang K, Simpson E, Randolph L, Luyt L, Yu X
Nano Lett. 2014; 14(3):1551-8.
PMID: 24499194
PMC: 4169141.
DOI: 10.1021/nl404816m.
Molecular imaging of inflammation in atherosclerosis.
Wildgruber M, Swirski F, Zernecke A
Theranostics. 2013; 3(11):865-84.
PMID: 24312156
PMC: 3841337.
DOI: 10.7150/thno.5771.
Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy.
Chen J, Pan H, Lanza G, Wickline S
Adv Chronic Kidney Dis. 2013; 20(6):466-78.
PMID: 24206599
PMC: 4074885.
DOI: 10.1053/j.ackd.2013.08.004.
New frontiers and developing applications in 19F NMR.
Yu J, Hallac R, Chiguru S, Mason R
Prog Nucl Magn Reson Spectrosc. 2013; 70:25-49.
PMID: 23540575
PMC: 3613763.
DOI: 10.1016/j.pnmrs.2012.10.001.
Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development.
Quillard T, Libby P
Circ Res. 2012; 111(2):231-44.
PMID: 22773426
PMC: 3412367.
DOI: 10.1161/CIRCRESAHA.112.268144.
Targeted Nanocarriers for Imaging and Therapy of Vascular Inflammation.
Chacko A, Hood E, Zern B, Muzykantov V
Curr Opin Colloid Interface Sci. 2011; 16(3):215-227.
PMID: 21709761
PMC: 3121175.
DOI: 10.1016/j.cocis.2011.01.008.